CVS Health: Q1 Beat and Raised Guidance Validate Turnaround Thesis

What happened

CVS Health delivered a strong Q1 beat with revenues of $100.4bn and adjusted EPS of $2.57, exceeding expectations and prompting a 2026 guidance raise. The improved medical benefit ratio of 84.6% signals that the Medicare utilization spike that pressured 2024 results is stabilizing as anticipated. Management now expects 2026 revenue of $405bn, adjusted EPS of $7.40, and cash flow from operations of $9.5bn, reflecting renewed operational momentum. This performance validates the master report's BUY thesis built on restructuring savings, transparent pricing models (TrueCost, CostVantage), and biosimilar adoption (Cordavis). The Q1 results suggest that CVS's integrated payer-PBM-pharmacy platform is regaining its earnings power, with the litigation overhang appearing manageable relative to core operations.

Implication

The Q1 earnings deliver tangible evidence that CVS's turnaround is on track, with the medical benefit ratio improvement being the most important metric to watch. The raised 2026 guidance provides a clear earnings trajectory that supports the current valuation multiple and could drive further upside. However, investors must remain vigilant about PBM regulatory risks and litigation developments, though the core business now shows resilience. The restructuring program and transparent pricing shifts are gaining credibility, which could lead to multiple expansion if execution continues. For long-term holders, the integrated platform and cash flow generation offer a favorable risk/reward, and the recent earnings de-risk the thesis materially.

Thesis delta

The Q1 beat and guidance raise materially de-risk the turnaround narrative, shifting the thesis from speculative recovery to confirmed execution. The medical benefit ratio improvement and raised cash flow guidance reinforce the view that 2024's headwinds are abating. Consequently, the investment case now hinges less on restructuring hopes and more on sustainable earnings growth, making CVS a more compelling buy at current multiples.